Lilly wins cancer drug patent dispute


Eli Lilly stands to gain billions of dollars in revenue from sales of chemotherapy drug Alimta in the US, after it won a legal battle to uphold a patent covering the drug’s use in combination with B vitamins.

When used alone, Alimta (pemetrexed) can have severe, potentially fatal side effects. Trials carried out by Lilly established that combining Alimta with folic acid and vitamin B12 reduced these effects. The compound patent is due to expire in 2017, but an additional patent covering the use of the drug with the vitamin supplements will last until 2022. Israel-based firm Teva Pharmaceutical Industries disputed the validity of this patent, saying that adding supplements to the drug was a logical approach to reducing side effects. But the court ruled in Lilly’s favour, concluding that the company had put significant resources into developing the treatment regimen.

The win could mean around $500 million (£302 million) extra in sales per year after 2017 for Lilly, making up for some losses after the patent on its best-selling drug – antidepressant Cymbalta – expired in December last year. In a bid to protect Alimta sales overseas, Lilly is also currently involved in similar court cases in the UK, Germany and with the EU Patent Office.


Related Content

Lilly freezes pay as patent cliff looms

24 July 2013 Business

news image

Drugmaker targets $400 million savings as two key patents near expiry

Business roundup

23 February 2012 Business

news image

Industry news, March 2012

Most Read

Self-cleaning sensors see the light

23 January 2015 Research

news image

Overcoming electrode fouling in biomedical and environmental detectors

Alkali metal explosion explained

26 January 2015 Research

news image

High-speed cameras help re-examine the chemistry behind a classic classroom demonstration

Most Commented

Alkali metal explosion explained

26 January 2015 Research

news image

High-speed cameras help re-examine the chemistry behind a classic classroom demonstration

What we mean when we talk about bonds

29 January 2015 Comments

news image

Santiago Alvarez delves into the debates and disagreements that surround one of chemistry's most fundamental concepts